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Background: Listeria monocytogenes meningitis is the third most common cause of bacterial meningitis and is
associated with high rates of mortality and unfavorable outcome.
Methods: We analyzed 101 cytokines, chemokines and complement factors in CSF of adult patients with Listeria
meningitis included in a prospective cohort study and compared these biomarkers between Listeria meningitis pa-
tients and negative controls, and between Listeriameningitis patientswith a favorable and an unfavorable outcome.
Results: CSF was available from 26 of 62 (42%) Listeria meningitis patients and 19 negative controls. Fifteen (58%)
Listeria meningitis patients had an unfavorable outcome. In Listeria meningitis CSF levels of 51 biomarkers were
signiﬁcantly elevated compared to negative controls after Bonferroni correction. The 11most signiﬁcantly elevated
(P b .01) biomarkers of unfavorable outcome in Listeria meningitis were markers of T-cell activation (sIL-2Rα,
sCD40L and IL-1), interferon-related (IFN-α2, IL-18, CX3CL1, CCL20), markers of complement activation (C3a),
and endothelial growth factor related (VEGF, CXCL7).
Conclusions: Our data suggest that T-cell activation, complement activation, interferon- and endothelial growth
factor production are important in the immune response to Listeria meningitis, and thereby inﬂuence outcome.
General signiﬁcance: Our study provides target pathways for further studies in the pathophysiology of Listeria
meningitis.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Bacterial meningitis is caused by Streptococcus pneumoniae and
Neisseria meningitidis in 85% of cases [1,2]. Listeria monocytogenes is the
third most common cause of bacterial meningitis (identiﬁed in 6% of
cases) and is associated with high mortality and rate of unfavorable out-
come [3,4]. Listeria meningitis is predominantly found in elderly and im-
munocompromisedpatients, but also occurs in previous healthy adults [5,
6]. In an explorative studywe assess the associations between cerebrospi-
nal ﬂuid (CSF) inﬂammatorymarkers and outcome in Listeria meningitis.
2. Materials and methods
We identiﬁed adults (N16 years of age) who had Listeria meningitis
established bypositive CSF culture andwere listed in the database of thenter for Infection and Immunity
y of Amsterdam, PO Box 22660,
2; fax: +31 205669374.
eek).
. This is an open access article underNetherlands Reference Laboratory for Bacterial Meningitis (NRLBM)
from March 2006 to April 2012. This laboratory receives CSF isolates
from approximately 85% of all patients with bacterial meningitis in the
Netherlands. Patients or their legal representatives received written
information concerning the study and were asked to give written
informed consent for participation. Patients with negative CSF cultures,
hospital-acquired bacterial meningitis, or neurosurgical devices,
and those within 1 month following neurosurgical procedure or
neurotrauma, were excluded. The study was approved by the Medical
Ethics Committee of the Academic Medical Center, University of
Amsterdam, the Netherlands.
Online case record forms were used to collect data on clinical fea-
tures, complications, treatment and outcome in adults with meningitis.
Patients with an altered immune status owing to splenectomy, diabetes
mellitus, cancer, alcoholism or the use of immunosuppressive drugs
were considered immunocompromised, as were patients infected
with HIV. Neurological examination was performed at discharge and
outcome was scored according to the Glasgow Outcome Scale. This
measurement scale is well validated, with scores varying from 1
(death) to 5 (good recovery) [7]. A favorable outcome was deﬁnedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Clinical and laboratory characteristics on admission of 26 adults with community-
acquired L. monocytogenesmeningitis, 2006–2012 cohort a.
Variable Frequency
Median age in years (IQR) 68 (57–74)
Male sex 20 (77)
Predisposing factors
Immunocompromised 15 (58)
Pre-treated with antibiotics 3 (12)
Triad of fever, neck stiffness, and change in mental status 8 (31)
Indexes of CSF inﬂammation
WBC count (cells/μL) 766 (225–2047)
b1000 cells/mL 15 (58)
Protein level (g/L) 2.4 (1.8–3.8)
CSF to blood glucose ratio 0.27 (0.16–0.39)
Dexamethasone treatment 14 (54)
Neurological complications 19 (73)
Systemic complications 15 (58)
Unfavorable outcome 15 (58)
Death 6 (23)
a Continuous data are presented as medians (interquartile range), dichotomous data
are presented as n (%)
45M.M. Koopmans et al. / BBA Clinical 1 (2014) 44–51as a score of 5, and an unfavorable outcome was deﬁned as a score
of 1–4.
In patients with Listeria meningitis, residual CSF from the diagnostic
lumbar puncture was collected, centrifuged, and supernatant was
aliquoted and stored at −80 °C until analysis. Control CSF samples
were collected from 19 patients in whom a lumbar puncture was
performed to rule out sub-arachnoid hemorrhage in patients eventually
diagnosed with benign thunderclap headache. All these CSF samples
had normal leukocyte count, total protein level and glucose concentra-
tion (Appendix A1). CSF cytokine, chemokine and complement factor
concentrations were determined with Luminex technology using a
Milliplex MAP assay, Millipore, Billerica, MA, USA. For complement
component C3a, iC3b, C5a and sC5b-9 levels the Microvue C3a, iC3b,
C5a and sC5b-9 Quidel ELISA kits, Quidel, San Diego, USA were used.
CSF complement component levels of C1q and MBL were measured
using the Hycult ELISA kits, Hycult Biotech, Uden, the Netherlands and
PAI-2 was measured using the USCN ELISA kit, USCN Life Sciences,
Hubei, China.
Cytokine, chemokine and complement factor levels were compared
between negative controls and patients with Listeria meningitis
and subsequently between patients with Listeria meningitis with an
unfavorable outcome and those with a favorable outcome. The Mann–
Whitney U-test was used to examine associations between cytokine,
chemokine and complement factor levels between groups. All statistical
tests were two-tailed, and for differences between negative controls
and patients a Bonferroni corrected p-Value below b .00051was consid-
ered signiﬁcant. In the comparison between patients with a favorable
and unfavorable outcome the limited number of patients prevented
correction for multiple testing. Therefore, we described biomarkers
with P value b .01. All statistical analyses were performed with SPSS
version 19.0.
3. Results
FromMarch 2006 to April 2012, 62 patients with Listeria meningitis
were identiﬁed of 1032 included episodes of bacterial meningitis (6%).
CSF was available for 26 patients (42%), with median age of 68 years
(interquartile range [IQR] 57–74). Patients for whom CSF was available
had higher scores on the Glasgow Coma Scale on admission compared
to those in whom CSF was not available (GCS 14 [IQR 11–15] vs. 11
[IQR 10–14], P = .03); other clinical and laboratory characteristics and
outcome were comparable between patients with and without CSF
available.
Table 1 shows the clinical and laboratory characteristics of 26 patients
with CSF available. The majority was male (77%) and 15 patients (58%)
had an immunocompromised state. Threepatients (13%)werenot immu-
nocompromised andwere 50 years old or younger.Median CSF leukocyte
count was 766 cells/mL (interquartile range [IQR] 255–2047), protein
level of 2.4 g/L (IQR 1.8–3.8) and CSF to blood glucose ratio of 0.27 (IQR
0.16–0.39). Adjunctive dexamethasone treatment was started with or
before the ﬁrst dose of antibiotics in 14 patients (54%) according to the
standard regimen of 10 mg every 6 h for 4 days. Data on diagnostic
sequence of cranial CT, lumbar puncture and initiation of treatment
were available for 20 patients. In 19 patients a cranial CT was made
prior to the lumbar puncture, and in only 6 the antibiotic treatment
was initiated before the CT. Fifteen patients (58%) had an unfavorable
outcome and 6 (23%) died.
Because of limited amounts of cerebrospinal ﬂuid not all assays
could be performed for all patients: sufﬁcient CSF to assess 46 analytes
was available from all 26 patients and 19 controls. The other 55 analytes
were tested in 19–25 patients and 13–18 controls (Appendix A2). Out
of 101 analytes, 10 (10%) were below the lower limit of detection in
all patient and control samples (IL-9, CCL1, CCL21, IL-33, LIF, TPO,
TSLP, MMP-12,MMP-13 andMMP-7). For 21 analytes (21%) the protein
concentration was below the lower limit of detection in all negative
control samples, but detectable concentrations were present in Listeriameningitis patients. Compared to negative controls, 51 of the 101
(50%) cytokines, chemokines and complement factors were signiﬁcant-
ly elevated in patients with Listeria meningitis after Bonferroni correc-
tion (b0.00051) for multiple testing.
We identiﬁed vascular endothelial growth factor (VEGF; P = .001,
Appendix A3, Fig. 1), and (Appendix A4) complement component C3a
(P = .002), soluble interleukin receptor antagonist a2 (sIL-2Rα; P =
.002), chemokine (C–X–C motif) ligand 7 (CXCL7; P = .003), CX3CL1
(P = .003), CCL11 (P = .005), interferon alpha2 (IFN-α2; P = .005),
chemokine (C–Cmotif) ligand 20 (CCL20; P= .007), interleukin 12 sub-
unit p40 (IL-12p40; P = .008), soluble CD40 ligand (sCD40L; P = .008)
and interleukin 18 (IL-18; P= .008) as the top 11 cytokines, chemokines
and complement factorswith the strongest association (P b .01)with un-
favorable outcome in patients with Listeria meningitis.
No differences in CSF biomarker levels were identiﬁed when
comparing patients in whom the lumbar puncture was performed
before or after parenteral antibiotics.
4. Discussion
In our explorative studywe assessed 101 cytokines, chemokines and
complement factors and found that VEGF, C3a, sIL-2Rα, CXCL7, CX3CL1,
CCL11, IFN-α2, CCL20, IL-12p40, IL-18, and sCD40L were most signiﬁ-
cantly different between Listeria meningitis patients with an unfavor-
able and those with a favorable outcome. These differences in protein
levels may reﬂect important pathways in the pathophysiology of
Listeria meningitis contributing to disease severity. VEGF, sIL-2Rα, C3a
and IFN-α2 have previously been identiﬁed to be involved in the host
defense mechanisms against L. monocytogenes [8–12].
VEGF is a growth factor and an angiogenic cytokine which is
expressed intracellularly in several cell types, such as macrophages, in-
side which L. monocytogenes replicate [8,13]. In vitro experiments have
previously shown that VEGF levels in RAW264.7 macrophage-like cells
were elevated following stimulation with heat-killed L. monocytogenes
[9]. Furthermore, an in vivo model showed elevated expression of
VEGF in splenic macrophages in mice with L. monocytogenes compared
to negative controls [14]. This production of VEGF is induced by CXCL7
[14], which was also elevated in patients with an unfavorable outcome.
VEGF has been shown to induce endothelial changes during bacterial
meningitis in patients and disrupt the blood brain barrier in a rat
model [15]; thereby increasing brain inﬂammation and oedema. Elevat-
ed VEGF levels,mediated by CXCL7, could result in increased brain dam-
age in patients explaining the increased rate of unfavorable outcome.
Fig. 1. Levels of top 11 cytokines, chemokines and complement factors with strongest association with unfavorable outcome in patients with Listeria meningitis. Footnote: Dots indicate
individual values, bars are medians and whiskers indicate interquartile range.
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Appendix A1
Clinical and laboratory characteristics of 26 patients in whom cytokine levels were
analyzed in CSF vs. 36 patients in whom cytokine levels were not analyzed in CSF. All 62
adults had community-acquired Listeria meningitis and were included in the prospective
cohort study between 2006 and 2012a.
Variable Patients with CSF
collection for analysis
N = 26 (%)
Patients without CSF
collection for analysis
N = 36 (%)
p-Value
Median age in years (IQR) 68 (57–74) 73 (62–77) 0.34
Male sex 20 (77) 19 (53) 0.05
Immunocompromised 15 (58) 29 (81) 0.05
Duration of symptoms b24 h 8 (31) 12 (33) 0.83
Glasgow Coma Scale (IQR) 14 (11–15) 11 (10–14) 0.03
b14 (indicating change
in mental status)
13 (50) 25 (69) 0.12
≤8 (indicating coma) 1 (4) 4 (11) 0.39
Indexes of CSF inﬂammation
WBC count (cells/mL) 766 (225–2047) 636 (367–1498) 0.89
b1000 cells/mL 15 (58) 24 (67) 0.47
Protein level (g/L) 2.4 (1.8–3.8) 2.6 (1.7–3.5) 0.99
CSF to blood glucose ratio 0.27 (0.16–0.39) 0.24 (0.06–0.34) 0.44
Dexamethasone treatment 14 (54) 19 (53) 0.92
Unfavorable outcome 15 (58) 23 (64) 0.62
Death 6 (23) 16 (44) 0.08
a Continuous data are presented as medians (interquartile range), dichotomous data
are presented as n (%).
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cruits antibodies and initiates the adaptive immune response [16]. A
study on the role of the complement in L. monocytogenes infections
showed that listerial opsonization mainly depended on the classical
complement pathway [17]. Following opsonization, activation of the
ﬁnal common pathway results in conversion of C3 to C3a and C3b [10,
16]. The degree of complement activation has previously been shown
to inﬂuence outcome in pneumococcal meningitis by aggravating
brain damage [18]. In a pneumococcal meningitis mousemodel inhi-
bition of complement factor 5 was shown to improve outcome [18].
The elevated C3a levels in patients with unfavorable outcome
suggest that complement activation is detrimental in Listeria men-
ingitis as well. Whether complement inhibition is a successful strat-
egy in Listeria meningitis is an interesting topic for experimental
studies.
Several proteins that were elevated in patients with an unfavorable
outcomewere involved in T-cell activation.We observed elevated levels
of sIL-2Rα, sCD40L and IL-12p40 in patients with an unfavorable out-
come indicating a strong T-cell activation, which has been shown to
be crucial in the immune response to L.monocytogenes inmousemodels
[19]. Activated T-cells express high afﬁnity receptors for interleukin-2,
which plays an important role during proliferation of T-lymphocytes.
This IL-2-receptor alpha is also released in a soluble form (sIL-2Ra),
which is considered to be an important marker of continuous T-cell
activation [20,21]. Another protein in the activation of T-cells which
was elevated in patients with an unfavorable outcome is sCD40L,
which is a member of the TNF family and results in T-cell priming
following infection with L. monocytogenes [22]. IL-12p40 is important
for sustaining a sufﬁcient number of memory/effector Th1 cells to
mediate long-term protection to intracellular pathogens, and acts on
T-cells and natural killer cells, which are both essential to combat
L. monocytogenes infection [23].
Other proteins that were identiﬁed to be elevated in patients with
unfavorable outcome were interferon (IFN-α2) or interferon-related
(IL-18, CX3CL1, CCL20). Type 1 interferons, which include interferon
alpha, have been shown to have a deleterious effect during
L.monocytogenes infection by decreasing the viability of infectedmacro-
phages [23,24]. The increased levels of IFN-α2 in patients with an
unfavorable outcome concur with these experimental studies. IFN-γ
on the other hand is essential during L. monocytogenes infection, and
provides early protection against the pathogen [23]. IL-18 a pro-
inﬂammatory cytokine that stimulates IFN-γ production in T-helper
type 1 cells and NK cells [25]. CX3CL1 and CCL20 are chemo-
attractants that are produced following stimulation by IFN-γ and result
in the recruitment of monocytes, NK cells and T-cells [26]. The higher
levels of IL-18, CX3CL1 and CCL20 were not paralleled by signiﬁcantly
elevated levels of IFN-γ in patients with an unfavorable outcome.
CCL11 (Eotaxin) is an eosinophil speciﬁc chemokine assumed to be
involved in eosinophilic inﬂammatory diseases. CCL11 production is
not related to interferons and does not inﬂuence T-cell activation [27].
Its role in L. monocytogenes infection has not been studied, and it is un-
clear how the elevated levels of CCL11 in patients with an unfavorable
outcome must be interpreted.
Our study has several limitations. First, only patients with a positive
CSF culture for L. monocytogenes were included in this study. Negative
CSF culture results occur in 11%–30% of patientswith bacterialmeningitis,
and this percentagemay be higher in patients with Listeria meningitis [1,
6,28,29]. Therefore, these patients are underrepresented in our cohort.
Second, as shown in Table 1, for the 26 patients we analyzed their cyto-
kine levels had a higher Glasgow Coma Scale compared to 36 patients
for whom no CSF was available. This implies a selection towards less se-
vere diseases in the studied population compared to the general popula-
tion of Listeria meningitis patients. Third, the number of patients is
insufﬁcient to correct for multiple testing in the analysis for outcome or
performmultivariate analyses. Therefore, the results must be interpreted
with caution, as type 1 errors may occur due to the high number ofvariables tested, and validation of our results in other cohorts is warrant-
ed. Fourth, the number of patients is insufﬁcient to analyze if the expres-
sion of biomarkers was inﬂuenced in subcategories such as the immune
state of the patients, or patients with systemic of neurological complica-
tions. Finally, it remains unclear whether the identiﬁed proteins have a
causative role in the development of unfavorable outcome or merely re-
ﬂect increased disease severity. Despite these limitations, this study on
CSF characteristics culture conﬁrmed that Listeriameningitis is the largest
series so far and gives insight in the pathophysiology of the disease.5. Conclusions
Our data suggest that VEGF production (VEGF, CXCL7), complement
activation (C3a), T-lymphocyte activation (sIL-2Rα, sCD40L, IL-12p40),
and interferon production (IFN-α2, IL-18, CCL20, CX3CL1) are the most
important elements of the immune response during Listeria meningitis,
andmay inﬂuence outcome. These datamay give leads to further inves-
tigation in the pathophysiology of Listeria meningitis.Funding
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Appendix A2
Out of 101 cytokines, chemokines and complement factors, 73 were signiﬁcantly elevated compared to negative controls. 51 were signiﬁcantly elevated after Bonferroni correction.
Variable N (LM/NC)a L. monocytogenesmeningitis
Median level (IQR)
Negative controls
Median level (IQR)
p-Value
EGF 26/19 151 pg/ml (62–313) 81 pg/ml (45–126) 0.012
CCL11 26/19 448 pg/ml (200–773) 81 pg/ml (28–126) b0.0001b
FGF2 26/19 962 pg/ml (584–1387) 484 pg/ml (136–731) b0.0001b
Flt3-Lig 26/19 250 pg/ml (98–290) 71 pg/ml (41–133) 0.002
CX3CL1 26/19 1.3 ng/ml (0.8–12) 0.5 ng/ml (0.4–0.7) b0.0001b
GCSF 26/19 11.3 ng/ml (5.4–16.5) 0.06 ng/ml (0.04–0.1) b0.0001b
GMCSF 26/19 269 pg/ml (119–1054) 18 pg/ml (9–31) b0.0001b
CXCL1 26/19 2.2 ng/ml (1.3–5.0) 0.06 ng/ml (0.02–0.09) b0.0001b
IFN-α2 26/19 938 pg/ml (628–1602) 67 pg/ml (7–125) b0.0001b
IL-1a 26/19 454 pg/ml (319–2420) 18 pg/ml (11–21) b0.0001b
IL-1b 26/19 189 pg/ml (91–492) 4 pg/ml (2–6) b0.0001b
IL-1ra 26/19 2.3 ng/ml (982–4305) 0.02 ng/ml (0.008–0.03) b0.0001b
IL-2 26/19 36 pg/ml (25–94) 4 pg/ml (3–7) b0.0001b
IL-3 26/19 15 pg/ml (8–31) 15 pg/ml (7–29) 0.696
IL-4 26/19 70 pg/ml (35–101) 82 pg/ml (25–116) 0.836
IL-5 26/19 10 pg/ml (6–15) 3.8 pg/ml (1.7–7.4) 0.001
IL-6 26/19 58 ng/ml (26–89) 0.01 ng/ml (0.009–0.03) b0.0001b
IL-7 26/19 163 pg/ml (95–1251) 92 pg/ml (25–139) 0.002
IL-8 26/19 11 ng/ml (5.6–19) 0.02 ng/ml (0.02–0.04) b0.0001b
IL-9 26/19 75 pg/ml (29–132) 42 pg/ml (22–83) 0.118
IL-10 26/19 408 pg/ml (171–1080) 3.7 pg/ml (1.8–6.4) b0.0001b
IL-12p40 26/19 338 pg/ml (213–1228) 69 pg/ml (12–103) b0.0001b
IL-12p70 26/19 141 pg/ml (77–207) 19 pg/ml (13–29) b0.0001b
IL-13 26/19 31 pg/ml (12–55) 11 pg/ml (5–28) 0.015
IL-15 26/19 53 pg/ml (25–83) 22 pg/ml (15–34) 0.005
IL-17 26/19 38 pg/ml (18–95) 4.8 pg/ml (3.2–5.3) b0.0001b
CCL2 26/19 17 ng/ml (5.7–69) 0.5 ng/ml (0.4–0.6) b0.0001b
CCL7 26/19 951 pg/ml (489–3556) 114 pg/ml (59–167) b0.0001b
CCL22 26/19 951 pg/ml (362–1232) 707 pg/ml (230–883) 0.093
CCL3 26/19 209 pg/ml (126–520) 125 pg/ml (51–142) 0.001
CCL4 26/19 1.5 ng/ml (0.6–4.2) 0.6 ng/ml (0.3–0.8) b0.0001b
PDGFABBB 26/19 158 pg/ml (58–333) 73 pg/ml (48–123) 0.066
CCL5 26/19 64 pg/ml (27–202) 20 pg/ml (10–29) 0.002
sCD40L 26/19 381 pg/ml (206–841) 76 pg/ml (50–104) b0.0001b
sIL-2Rα 26/19 186 pg/ml (85–491) 55 pg/ml (24–96) b0.0001b
TGFα 26/19 17 pg/ml (7–32) 16 pg/ml (10–26) 0.597
TNFα 26/19 319 pg/ml (212–639) 50 pg/ml (32–61) b0.0001b
TNFβ 26/19 43 pg/ml (20–441) 15 pg/ml (10–24) 0.001
VEGF 26/19 1.2 ng/ml (0.7–1.9) 0.5 ng/ml (0.4–0.7) b0.0001b
IL-18 26/19 6.9 ng/ml (4.8–18) 0.7 ng/ml (0.4–0.9) b0.0001b
vWFAg 17/12 3 pg/ml (2–9) 0.4 pg/ml (0.11–0.51) b0.0001b
Fibrinog\en 17/12 0.55 pg/ml (0.2–0.6) 0.05 pg/ml (0.03–0.06) b0.0001b
TAFI 17/12 1.3 pg/ml (0.8–2.5) 0.38 pg/ml (0.11–0.54) 0.002
CCL8 19/18 7.8 ng/ml (4.1–35) 0.1 ng/ml (0.09–0.2) b0.0001b
CCL13 19/18 301 pg/ml (103–392) 333 pg/ml (200–436) 0.313
ENA-78 19/18 470 pg/ml (378–701) 577 pg/ml (271–733) 0.775
CXCL12 19/18 2.3 ng/ml (1163–3824) 2.0 ng/ml (0.9–3.2) 0.538
CXCL13 19/18 16 pg/ml (8–29) 2.9 pg/ml (0.6–6.5) b0.0001b
CCL1 19/18 28 pg/ml (10–57) 47 pg/ml (29–65) 0.092
IL-16 19/18 247 pg/ml (64–46) 280 pg/ml (176–459) 0.799
MIP-1d 19/18 501 pg/ml (146–710) 88 pg/ml (35–121) b0.0001b
CCL17 19/18 2.7 pg/ml (1.1–4.2) 1.7 pg/ml (0.7–2.5) 0.092
CCL21 19/18 698 pg/ml (374–871) 714 pg/ml (482–922) 0.558
CCL24 19/18 54 pg/ml (21–84) 24 pg/ml (10–29) 0.008
CCL26 19/18 57 pg/ml (35–144) 41 pg/ml (27–78) 0.210
CCL27 19/18 25 pg/ml (6–61) 8 pg/ml (6–12) 0.053
IL-23 19/18 233 pg/ml (144–463) 234 pg/ml (143–443) 0.893
LIF 19/18 599 pg/ml (346–734) 636 pg/ml (439–828) 0.313
TPO 19/18 932 pg/ml (513–1299) 968 pg/ml (328–1747) 0.822
TRAIL 19/18 151 pg/ml (68–229) 10 pg/ml (4–23) b0.0001b
SCF 19/18 40 pg/ml (25–73) 21 pg/ml (10–27) 0.001
TSLP 19/18 73 pg/ml (52–97) 45 pg/ml (23–85) 0.16
IL-20 19/18 1.7 ng/ml (1.4–2.7) 1.5 ng/ml (0.9–2.6) 0.27
IL-21 19/18 41 pg/ml (25–67) 20 pg/ml (3–41) 0.020
IL-28A 19/18 82 pg/ml (40–108) 68 pg/ml (34–102) 0.46
IL-33 19/18 138 pg/ml (87–163) 78 pg/ml (34–148) 0.06
MCSF 19/18 28 ng/ml (13–37) 1.5 ng/ml (1.2–2.7) b0.0001b
CXCL7 19/18 5.1 ng/ml (2.6–8.3) 0.5 ng/ml (0.09–0.6) b0.0001b
CXCL6 19/18 258 pg/ml (164–1172) 18 pg/ml (11–25) b0.0001b
CCL14a 19/18 7.5 ng/ml (4.3–13) 1.2 ng/ml (0.9–18) b0.0001b
CCL19 19/18 153 pg/ml (76–303) 79 pg/ml (38–98) 0.003
CCL20 19/18 779 pg/ml (280–1857) 23 pg/ml (10–28) b0.0001b
XCL1 19/18 1.3 ng/ml (0.4–1.5) 0.6 ng/ml (0.2–0.8) 0.007
IL-11 19/18 3.2 ng/ml (1.8–4.4) 2.1 ng/ml (1.3–2.7) 0.026
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Appendix A2 (continued)
Variable N (LM/NC)a L. monocytogenesmeningitis
Median level (IQR)
Negative controls
Median level (IQR)
p-Value
IL-29 19/18 3.3 ng/ml (1.5–4.3) 1.2 ng/ml (0.5–2.1) 0.004
MMP-3 26/18 23 ng/ml (10–39) 1 ng/ml (0.7–1.9) b0.0001b
MMP-12 26/18 6 ng/ml (4.1–9) 7.8 ng/ml (4–13.4) 0.34
MMP-13 26/18 4.6 ng/ml (2.4–6.7) 4.9 ng/ml (1.6–8.4) 0.63
CFH 25/18 7 ng/ml (4.8–9.1) 1.1 ng/ml (0.9–1.5) b0.0001b
MMP-1 25/18 683 pg/ml (216–937) 333 pg/ml (158–594) 0.030
MMP-2 25/18 17 ng/ml (7.7–32) 26 ng/ml (9.7–33) 0.46
MMP-7 25/18 10 ng/ml (4.9–16) 128 ng/ml (7.1–160) 0.56
MMP-9 25/18 387 ng/ml (120–497) 0.1 ng/ml (0.06–0.2) b0.0001b
MMP-10 25/18 266 pg/ml (154–275) 114 pg/ml (65–190) 0.003
ICAM 26/19 64 pg/ml (46–121) 2.3 pg/ml (1.0-5.1) b0.0001b
tPAI-1 26/19 50 ng/ml (28–83) 0.8 ng/ml (0.6–1.8) b0.0001b
MIF 26/13 1.5 ng/ml (0.6-5.1) 0.8 ng/ml (0.6–1.6) 0.16
C3a 25/19 171 pg/ml (112–369) 5.8 pg/ml (4–9) b0.0001b
iC3b 25/19 15 pg/ml (8–21) 3.5 pg/ml (2.7–4.7) b0.0001b
C5a 18/14 3.2 pg/ml (1.1-8.8) 0 pg/ml (0–0.4) b0.0001b
C5b9 18/14 415 pg/ml (95–1294) 155 pg/ml (64–394) 0.14
IFN-γ 26/19 1.1 ng/ml (2.4-19) 0.02 ng/ml (0.009–0.03) b0.0001b
CXCL9 19/18 81 ng/ml (21–357) 0.12 ng/ml (0.04–0.17) b0.0001b
CXCL10 26/19 488 ng/ml (485–488) 0.4 ng/ml (0.1–0.7) b0.0001b
PDGFAA 26/19 78 pg/ml (54–176) 50 pg/ml (21–73) 0.001
CXCL11 19/18 15 ng/ml (4.3–25) 0.01 ng/ml (0.008–0.02) b0.0001b
C3 25/18 7.6 ng/ml (0.1–12) 1.8 ng/ml (0.2–5.4) 0.008
VCAM 26/19 394 pg/ml (290–527) 42 pg/ml (34–51) b0.0001b
PAI-2 26/14 240 ng/ml (168–319) 18 ng/ml (0.3–27) b0.0001b
MBL 21/19 11 ng/ml (3.9–17) 3 ng/ml (2–3.8) b0.0001b
C1q 21/19 152 ng/ml (118–245) 114 ng/ml (75–139) 0.009
a Number of Listeria meningitis (LM) patients and number of negative controls (NC) for whom enough CSF was available to measure the analyte.
b Signiﬁcantly elevated in L. monocytogenesmeningitis patients compared to negative controls after Bonferroni correction (P b 0.00051).
Appendix A3
Top 11 cytokines, chemokines and complement factors with strongest association with an unfavorable outcome in patients with Listeria meningitis.
Cytokine, chemokine or complement factor Unfavorable outcome (n = 15)
Median level (IQR)a
Favorable outcome (n = 11)
Median level (IQR)
p-Value
VEGF 1.2 ng/ml (1.7–2.3) 0.8 ng/ml (0.2–1.1) .001
C3a 9.1 μg/ml (5.8–10.7) 3.2 μg/ml (1.7–5.2) .002
sIL-2Rα 338 pg/ml (139–500) 112 pg/ml (62–170) .002
CXCL7 426 pg/ml (159–573) 119 pg/ml (64–159) .003
CX3CL1 7.6 ng/ml (1.2–13.9) 0.8 ng/ml (0.6–1.3) .003
CCL11 688 pg/ml (442–942) 292 pg/ml (153–425) .005
IFN-α2 1.4 ng/ml (0.9–2.0) 0.7 ng/ml (0.3–0.9) .005
CCL20 2.2 ng/ml (1.2–4.8) 0.4 ng/ml (0.2–0.8) .007
IL-12p40 803 pg/ml (335–1374) 228 pg/ml (106–294) .008
sCD40 701 pg/ml (334–1162) 264 pg/ml (168–396) .008
IL-18 9.8 ng/ml (5.7–25.7) 4.9 ng/ml (3.7–9.1) .008
a IQR = interquartile range.
Appendix A4
Level of association in 101 cytokines, chemokines and complement factorswith an unfavorable outcome in 15 Listeriameningitis patients compared to 11 Listeriameningitis patientswith
favorable outcome.
Variable Unfavorable outcome (n = 15) median level (IQR)a Favorable outcome (n = 11) median level (IQR) p-Value
EGF 195 pg/ml (139–566) 101 pg/ml (59–162) 0.02
CCL11 688 ng/ml (442–942) 292 pg/ml (152–425) 0.005
FGF2 1.4 ng/ml (0.9–1.6) 699 pg/ml (338–1029) 0.01
Flt3-Lig 264 ng/ml (62–321) 241 pg/ml (114–282) 0.80
CX3CL1 7.6 ng/ml (1.2–14) 761 pg/ml (608–1258) 0.003
GCSF 8.3 ng/ml (5.8–16) 14 ng/ml (4.0–18) 0.68
GMCSF 497 pg/ml (208–1191) 158 pg/ml (104–274) 0.02
CXCL1 2.7 ng/ml (1.1–9.9) 2.2 ng/ml (1.7–3.7) 0.84
IFN-α2 1.4 ng/ml (0.9–1.9) 658 pg/ml (323–897) 0.005
IL-1a 1.5 ng/ml (0.4–3.0) 383 pg/ml (317–451) 0.04
IL-1b 151 pg/ml (96–591) 206 pg/ml (71–430) 0.92
IL-1ra 2.4 ng/ml (1.9–9.9) 993 pg/ml (723–2718) 0.03
IL-2 34 pg/ml (25–98) 37 pg/ml (24–93) 0.92
IL-3 16 pg/ml (8.2–32) 14 pg/ml (6.5–31) 0.99
IL-4 70 pg/ml (35–100) 64 pg/ml (20–104) 0.76
(continued on next page)
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Appendix A4 (continued)
Variable Unfavorable outcome (n = 15) median level (IQR)a Favorable outcome (n = 11) median level (IQR) p-Value
IL-5 10 pg/ml (7.3–14) 10 pg/ml (5.4–21) 0.99
IL-6 50 ng/ml (28–99) 59 ng/ml (14–78) 0.57
IL-7 989 pg/ml (133–1764) 123 pg/ml (69–174) 0.04
IL-8 12 ng/ml (5.3–26) 7.2 ng/ml (6.1–16) 0.92
IL-9 102 pg/ml (67–148) 55 pg/ml (10–73) 0.01
IL-10 439 pg/ml (175–1985) 290 pg/ml (134–827) 0.33
IL-12p40 803 pg/ml (335–1374) 228 pg/ml (106–294) 0.008
IL-12p70 146 pg/ml (81–216) 98 pg/ml (53–203) 0.47
IL-13 7 pg/ml (8–48) 42 pg/ml (14–74) 0.36
IL-15 67 pg/ml (29–83) 50 pg/ml (17–90) 0.68
IL-17 43 pg/ml (16–58) 37 pg/ml (19–115) 0.99
CCL2 20 ng/ml (6–31) 7.0 ng/ml (2.7–10) 0.84
CCL7 1.1 ng/ml (0.6–7.4) 653 pg/ml (436–1944) 0.18
CCL22 15 pg/ml (248–1216) 1.2 ng/ml (0.5–1.3) 0.36
CCL3 394 pg/ml (154–663) 155 pg/ml (107–209) 0.07
CCL4 1.7 ng/ml (1–4.2) 1.0 ng/ml (0.5–5.2) 0.51
PDGFABBB 100 pg/ml (51–328) 178 pg/ml (83–336) 0.36
CCL5 98 pg/ml (23–219) 48 pg/ml (28–199) 0.76
sCD40L 701 pg/ml (334–1162) 264 pg/ml (168–396) 0.008
sIL-2Rα 426 pg/ml (159–573) 119 pg/ml (65–159) 0.002
TGFα 16.6 pg/ml (7.6–32) 20 pg/ml (3.2–33) 0.88
TNFα 331 pg/ml (242–771) 307 pg/ml (108–558) 0.33
TNFβ 272 pg/ml (28–622) 25 pg/ml (18–55) 0.04
VEGF 1.7 ng/ml (1.2–2.3) 832 pg/ml (235–1134) 0.001
IL-18 9.8 ng/ml (5.7–26) 4.9 ng/ml (3.7–9.1) 0.008
vWFAg 7.8 pg/ml (4.1–20) 2.5 pg/ml (1.3–3.9) 0.02
Fibrinog\en 0.6 pg/ml (0.5–0.6) 0.2 pg/ml (0.2–0.6) 0.03
TAFI 2.1 pg/ml (1.0–3) 1.1 pg/ml (0.5–2.4) 0.42
CCL8 20 ng/ml (7.6–63) 5.9 ng/ml (2.2–30) 0.04
CCL13 239 pg/ml (96–392) 301 pg/ml (189–397) 0.91
ENA-78 474 pg/ml (282–680) 470 pg/ml (386–740) 0.35
CXCL12 1.8 ng/ml (1.2–3.2) 3.6 ng/ml (870–4.0) 0.40
CXCL13 20 pg/ml (12–77) 16 pg/ml (7.7–29) 0.35
CCL1 47 pg/ml (16–64) 24 pg/ml (9.4–46) 0.31
IL-16 298 pg/ml (198–515) 247 pg/ml (158–464) 0.66
MIP-1d 702 pg/ml (311–737) 315 pg/ml (78–634) 0.24
CCL17 2.6 pg/ml (0.6–3.9) 3.1 pg/ml (1.7–4.7) 0.44
CCL21 613 pg/ml (140–1021) 698 pg/ml (454–871) 0.72
CCL24 75 pg/ml (19–102) 45 pg/ml (24–62) 0.24
CCL26 66 pg/ml (49–156) 57 pg/ml (15–91) 0.40
CCL27 51 pg/ml (9.6–74) 9 pg/ml (5.9–38) 0.15
IL-23 259 pg/ml (138–437) 233 pg/ml (178–467) 0.72
LIF 465 pg/ml (242–754) 637 pg/ml (475–734) 0.35
TPO 954 pg/ml (503–1291) 859 pg/ml (513–1449) 0.84
TRAIL 227 pg/ml (133–349) 83 pg/ml (44–153) 0.03
SCF 54 pg/ml (28–98) 35 pg/ml (24–54) 0.31
TSLP 71 pg/ml (27–116) 76 pg/ml (54–97) 0.78
IL-20 1.6 ng/ml (0.8–2.9) 1.8 ng/ml (1.5–2.7) 0.49
IL-21 50 pg/ml (27–96) 35 pg/ml (6.2–57) 0.44
IL-28A 110 pg/ml (88–165) 54 pg/ml (15–91) 0.002a
IL-33 161 pg/ml (99–184) 96 pg/ml (64–157) 0.08
MCSF 31 ng/ml (28–49) 17 ng/ml (11–34) 0.09
CXCL7 9.1 ng/ml (5.8–11) 3.2 ng/ml (1.7–5.2) 0.003
CXCL6 658 pg/ml (111–1591) 258 pg/ml (164–1171) 0.97
CCL14a 13 ng/ml (5.5–19) 6.2 ng/ml (4.3–7.6) 0.11
CCL19 130 pg/ml (62–191) 213 pg/ml (114–308) 0.27
CCL20 2.2 ng/ml (1.2–4.8) 399 pg/ml (224–779) 0.007
XCL1 675 pg/ml (362–1488) 1.4 ng/ml (0.7–1.5) 0.27
IL-11 3.8 ng/ml (1.6–5.8) 3.2 ng/ml (2.6–4.4) 0.72
IL-29 3.4 ng/ml (2.8–3.8) 1.8 pg/ml (0.9–4.9) 0.91
MMP-3 23 ng/ml (10–42) 23 ng/ml (7.9–37) 0.76
MMP-12 6.0 ng/ml (4.2–11) 6.0 ng/ml (3.8–8.9) 0.92
MMP-13 3.4 ng/ml (2.3–6.3) 5.4 ng/ml (3.2–7.8) 0.12
CFH 7.5 ng/ml (4.2–11) 6.0 ng/ml (5.4–8.0) 0.27
MMP-1 892 pg/ml (345–1296) 521 pg/ml (163–824) 0.18
MMP-2 16 ng/ml (6.2–32) 22 ng/ml (9.3–33) 0.54
MMP-7 11 ng/ml (4.7–16) 9.2 ng/ml (4.8–16) 0.61
MMP-9 412 ng/ml (103–497) 387 ng/ml (129–497) 0.65
MMP-10 266 pg/ml (258–290) 235 pg/ml (54–278) 0.13
ICAM 83 pg/ml (59–136) 52 pg/ml (43–92) 0.11
tPAI-1 50 pg/ml (28–101) 51 pg/ml (28–77) 0.92
MIF 1.3 ng/ml (0.6–5.0) 1.5 ng/ml (0.6–6.9) 0.57
C3a 338 pg/ml (139–500) 112 pg/ml (62–170) 0.002
iC3b 18.5 pg/ml (8.3–42) 10 pg/ml (3.3–16) 0.08
C5a 8 pg/ml (2.5–16) 1.4 pg/ml (0.4–5.3) 0.03
C5b9 1.3 ng/ml (0.4–1.7) 147 pg/ml (41–435) 0.006a
IFN-γ 15 ng/ml (5.2–41) 2.7 pg/ml (1.4–16) 0.04
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Appendix A4 (continued)
Variable Unfavorable outcome (n = 15) median level (IQR)a Favorable outcome (n = 11) median level (IQR) p-Value
CXCL9 392 ng/ml (62–582) 57 ng/ml (20–252) 0.09
CXCL10 488 ng/ml (487–488) 487 ng/ml (476–488) 0.84
PDGFAA 86 pg/ml (52–168) 77 pg/ml (55–213) 0.99
CXCL11 17 ng/ml (11–25) 4.8 ng/ml (2.8–18) 0.18
C3 3.4 ng/ml (0.5–8.3) 12 ng/ml (3.3–18) 0.03
VCAM 3.9 ng/ml (2.7–5.5) 3.3 ng/ml (3.0–5.3) 0.96
PAI-2 279 ng/ml (221–342) 171 ng/ml (165–301) 0.06
MBL 11.0 ng/ml (3.9–23.5) 11.9 ng/ml (5.0–14.9) 0.75
C1q 176 ng/ml (130–295) 144 ng/ml (40–215) 0.22
a Variable is signiﬁcantly elevated in patients with Listeria meningitis with an unfavorable outcome compared to favorable outcome, but not compared to negative controls.
(See Appendix A4.)
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